Issue 2, 2023

The war on hTG2: warhead optimization in small molecule human tissue transglutaminase inhibitors

Abstract

Human tissue transglutaminase (hTG2) is a multifunctional enzyme with protein cross-linking and G-protein activity, both of which have been implicated in the progression of diseases such as fibrosis and cancer stem cell propagation when dysregulated, prompting the development of small molecule targeted covalent inhibitors (TCIs) possessing a crucial electrophilic ‘warhead’. In recent years there have been significant advances in the library of warheads available for the design of TCIs; however, the exploration of warhead functionality in hTG2 inhibitors has remained relatively stagnant. Herein, we describe a structure–activity relationship study entailing rational design and synthesis for systematic variation of the warhead on a previously reported small molecule inhibitor scaffold, and rigorous kinetic evaluation of inhibitory efficiency, selectivity, and pharmacokinetic stability. This study reveals a strong influence on the kinetic parameters kinact and KI with even subtle variation in warhead structure, suggesting that the warhead plays a significant role in not only reactivity, but also binding affinity, which consequently extends to isozyme selectivity. Warhead structure also influences in vivo stability, which we model by measuring intrinsic reactivity with glutathione, as well as stability in hepatocytes and in whole blood, giving insight into degradation pathways and relative therapeutic potential of different functional groups. This work provides fundamental structural and reactivity information highlighting the importance of strategic warhead design for the development of potent hTG2 inhibitors.

Graphical abstract: The war on hTG2: warhead optimization in small molecule human tissue transglutaminase inhibitors

Supplementary files

Article information

Article type
Research Article
Submitted
18 ربيع الأول 1444
Accepted
21 ربيع الثاني 1444
First published
01 جمادى الأولى 1444

RSC Med. Chem., 2023,14, 277-298

The war on hTG2: warhead optimization in small molecule human tissue transglutaminase inhibitors

L. Mader, S. K. I. Watt, H. R. Iyer, L. Nguyen, H. Kaur and J. W. Keillor, RSC Med. Chem., 2023, 14, 277 DOI: 10.1039/D2MD00378C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements